Janux Therapeutics, Inc. ( JANX) - Key Metrics
JANX Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0.16 | -$0.35 | $0 | -$0.01 |
| 2026Q1 | $0.06 | -$0.39 | -$0.20 | -$0.20 |
| 2025Q4 | $0.13 | -$0.52 | -$0.46 | -$0.46 |
| 2025Q3 | $0.16 | -$0.39 | -$0.21 | -$0.21 |
| 2025Q2 | $0 | -$0.55 | -$0.38 | -$0.39 |
JANX Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -10.97 |
| 2026Q1 | 0% | -8.91 |
| 2025Q4 | 0% | -6.76 |
| 2025Q3 | 0% | -15.67 |
| 2025Q2 | 0% | -10.50 |
JANX
Price: $16.51
52 week price:
Earnings Per Share: -1.64 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 219876
Market Capitalization: 1.0 billion